Exclusive: GSK Head Of Research Due In Shanghai Thursday To Begin Detailed Audit Of China R&D Operations
This article was originally published in PharmAsia News
Executive Summary
In an internal email, Patrick Vallance, GlaxoSmithKline’s president for pharmaceutical R&D, says he will arrive in Shanghai June 13 to help look for answers on how a paper authored by members of GSK’s China R&D unit misrepresented data. The incident has led to the dismissal of China R&D head Jingwu Zang, who spoke to PharmAsia News about the swirling controversy.